Medical device company LeMaitre Vascular (NASDAQ: LMAT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 11.3% year on year to $67.97 million. On the other hand, next quarter’s revenue guidance of $70.9 million was less impressive, coming in 1.8% below analysts’ estimates. Its GAAP profit of $0.65 per share was 5.1% below analysts’ consensus estimates.

Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

LeMaitre’s latest quarter was met with a negative market reaction as investors digested mixed results. While the company delivered double-digit organic revenue growth, management pointed to operational challenges that tempered overall profitability. CEO George LeMaitre cited strong demand for biologic products and robust expansion in international markets as key drivers, but also acknowledged capacity constraints in processing cardiac allografts. The sales force expansion and continued investment in global infrastructure contributed to higher operating expenses, and the discontinuation of a product line led to a one-time inventory charge.

Looking ahead, management’s guidance reflects ongoing investments in commercial infrastructure, new product launches, and integration of the recently acquired B. Braun vascular assets. CEO George LeMaitre noted that foreign exchange headwinds and a gradual sales transition for the acquired portfolio are expected to weigh on near-term results. The company is prioritizing approvals for longer Artegraft products and expansion into new markets, but CFO Dorian LeBlanc cautioned that margin improvement will depend on successfully managing costs and ramping up new manufacturing capacity.

Key insights from management’s remarks

Management attributed quarterly growth to biologics, international expansion, and a larger sales force, while noting that integration efforts, operational investments, and FX pressures affected margins and guidance.

• Biologics drive growth: Artegraft and RestoreFlow allografts outperformed, with Artegraft up 18% and RestoreFlow up 34%. International Artegraft sales grew, aided by new country approvals and ongoing expansion of indications, especially in Brazil and Saudi Arabia.
• Sales force and infrastructure expansion: The company increased its sales rep count by 19 year-over-year, reaching 171, and opened or planned seven new international offices and warehouses to improve customer reach and local service. These investments contributed to higher operating expenses.
• B. Braun acquisition: LeMaitre acquired polyester and silver-coated vascular grafts, valve cutters, and vein strippers from B. Braun, marking its third polyester graft acquisition. The transition adds scale in Europe and supports plans for direct sales in more markets, but management expects some customer “breakage” during the handover process.
• Gross margin improvement offset by charges: Gross margin increased year-over-year, driven by higher average selling prices and reduced shipping costs, but was partially offset by a $0.5 million inventory reserve for discontinuing the FAS-TIP product line. Excluding this charge, adjusted gross margin saw a further boost.
• Manufacturing and quality capacity constraints: RestoreFlow cardiac allograft growth was limited by internal processing bottlenecks, not supply, leaving potential sales untapped. Management is prioritizing hiring in quality and regulatory functions to address these constraints and meet surging demand.

Drivers of future performance

LeMaitre’s outlook is shaped by new product launches, international expansion, and ongoing integration of acquired assets, but tempered by operational and foreign exchange headwinds.

• Sales transition and FX challenges: The gradual transfer of the B. Braun portfolio will take up to two years, with revenue recognition tied to contract transitions. Management anticipates some initial customer attrition and ongoing FX headwinds, which have already impacted reported revenue and margin guidance.
• Capacity and cost management: Expanding manufacturing in Burlington and hiring for quality and regulatory roles are expected to alleviate current bottlenecks in processing biologics, especially cardiac allografts. However, increased commercial investments and transfer costs from acquired facilities may pressure operating margins in the near term.
• Product pipeline and global reach: The company is targeting regulatory approvals for expanded Artegraft indications (including longer grafts) in key international markets and progressing with facility and sales office openings. These efforts are expected to support medium-term growth once integration hurdles are overcome and new products come to market.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace and success of the B. Braun asset transition, including customer retention and ramp-up of direct sales, (2) the company’s progress in resolving manufacturing and quality bottlenecks for high-growth biologics, and (3) the regulatory approval timeline for new Artegraft product variants and expansion into new markets. Execution on these fronts will be critical for sustained growth and margin improvement.

LeMaitre currently trades at $78.75, down from $87.92 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.